These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 21768095)
21. Glycosylation status of nicastrin influences catalytic activity and substrate preference of γ-secretase. Moniruzzaman M; Ishihara S; Nobuhara M; Higashide H; Funamoto S Biochem Biophys Res Commun; 2018 Jul; 502(1):98-103. PubMed ID: 29787759 [TBL] [Abstract][Full Text] [Related]
22. Mutation analysis of the presenilin 1 N-terminal domain reveals a broad spectrum of gamma-secretase activity toward amyloid precursor protein and other substrates. Gong P; Vetrivel KS; Nguyen PD; Meckler X; Cheng H; Kounnas MZ; Wagner SL; Parent AT; Thinakaran G J Biol Chem; 2010 Dec; 285(49):38042-52. PubMed ID: 20921220 [TBL] [Abstract][Full Text] [Related]
23. A presenilin-1 mutation identified in familial Alzheimer disease with cotton wool plaques causes a nearly complete loss of gamma-secretase activity. Heilig EA; Xia W; Shen J; Kelleher RJ J Biol Chem; 2010 Jul; 285(29):22350-9. PubMed ID: 20460383 [TBL] [Abstract][Full Text] [Related]
24. Reduced Alzheimer's disease ß-amyloid deposition in transgenic mice expressing S-palmitoylation-deficient APH1aL and nicastrin. Meckler X; Roseman J; Das P; Cheng H; Pei S; Keat M; Kassarjian B; Golde TE; Parent AT; Thinakaran G J Neurosci; 2010 Dec; 30(48):16160-9. PubMed ID: 21123562 [TBL] [Abstract][Full Text] [Related]
25. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. Bentahir M; Nyabi O; Verhamme J; Tolia A; Horré K; Wiltfang J; Esselmann H; De Strooper B J Neurochem; 2006 Feb; 96(3):732-42. PubMed ID: 16405513 [TBL] [Abstract][Full Text] [Related]
26. Specific combinations of presenilins and Aph1s affect the substrate specificity and activity of γ-secretase. Yonemura Y; Futai E; Yagishita S; Kaether C; Ishiura S Biochem Biophys Res Commun; 2016 Sep; 478(4):1751-7. PubMed ID: 27608597 [TBL] [Abstract][Full Text] [Related]
27. Excess of nicastrin in brain results in heterozygosity having no effect on endogenous APP processing and amyloid peptide levels in vivo. Brijbassi S; Amtul Z; Newbigging S; Westaway D; St George-Hyslop P; Rozmahel RF Neurobiol Dis; 2007 Feb; 25(2):291-6. PubMed ID: 17071095 [TBL] [Abstract][Full Text] [Related]
28. TASTPM mice expressing amyloid precursor protein and presenilin-1 mutant transgenes are sensitive to γ-secretase modulation and amyloid-β₄₂ lowering by GSM-10h. Hussain I; Harrison DC; Hawkins J; Chapman T; Marshall I; Facci L; Ahmed S; Brackenborough K; Skaper SD; Mead TL; Smith BB; Giblin GM; Hall A; Gonzalez MI; Richardson JC Neurodegener Dis; 2011; 8(1-2):15-24. PubMed ID: 20689247 [TBL] [Abstract][Full Text] [Related]
29. Evidence That the "Lid" Domain of Nicastrin Is Not Essential for Regulating γ-Secretase Activity. Zhang X; Sullivan E; Scimeca M; Wu X; Li YM; Sisodia SS J Biol Chem; 2016 Mar; 291(13):6748-53. PubMed ID: 26887941 [TBL] [Abstract][Full Text] [Related]
30. Nicastrin functions as a gamma-secretase-substrate receptor. Shah S; Lee SF; Tabuchi K; Hao YH; Yu C; LaPlant Q; Ball H; Dann CE; Südhof T; Yu G Cell; 2005 Aug; 122(3):435-47. PubMed ID: 16096062 [TBL] [Abstract][Full Text] [Related]
31. Nicastrin, presenilin, APH-1, and PEN-2 form active gamma-secretase complexes in mitochondria. Hansson CA; Frykman S; Farmery MR; Tjernberg LO; Nilsberth C; Pursglove SE; Ito A; Winblad B; Cowburn RF; Thyberg J; Ankarcrona M J Biol Chem; 2004 Dec; 279(49):51654-60. PubMed ID: 15456764 [TBL] [Abstract][Full Text] [Related]
32. Familial Alzheimer's disease mutations in amyloid protein precursor alter proteolysis by γ-secretase to increase amyloid β-peptides of ≥45 residues. Devkota S; Williams TD; Wolfe MS J Biol Chem; 2021; 296():100281. PubMed ID: 33450230 [TBL] [Abstract][Full Text] [Related]
33. Beta-amyloid secretases and beta-amloid degrading enzyme expression in lens. Li G; Percontino L; Sun Q; Qazi AS; Frederikse PH Mol Vis; 2003 May; 9():179-83. PubMed ID: 12740567 [TBL] [Abstract][Full Text] [Related]
34. Genes and mechanisms involved in beta-amyloid generation and Alzheimer's disease. Steiner H; Capell A; Leimer U; Haass C Eur Arch Psychiatry Clin Neurosci; 1999; 249(6):266-70. PubMed ID: 10653281 [TBL] [Abstract][Full Text] [Related]
35. The adipocyte differentiation protein APMAP is an endogenous suppressor of Aβ production in the brain. Mosser S; Alattia JR; Dimitrov M; Matz A; Pascual J; Schneider BL; Fraering PC Hum Mol Genet; 2015 Jan; 24(2):371-82. PubMed ID: 25180020 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies. Evin G; Sernee MF; Masters CL CNS Drugs; 2006; 20(5):351-72. PubMed ID: 16696577 [TBL] [Abstract][Full Text] [Related]
37. Intracellular trafficking of presenilin 1 is regulated by beta-amyloid precursor protein and phospholipase D1. Liu Y; Zhang YW; Wang X; Zhang H; You X; Liao FF; Xu H J Biol Chem; 2009 May; 284(18):12145-52. PubMed ID: 19276086 [TBL] [Abstract][Full Text] [Related]
38. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883 [TBL] [Abstract][Full Text] [Related]